The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Research reveals that most gay and bisexual men who stop taking pre-exposure prophylaxis (PrEP) in the USA do so because it is too expensive or they see themselves as no longer having a need for it.
A review of abstinence-only education policies and programmes in the United States (USA) found they violated human rights, stigmatised or excluded youth, reinforced gender stereotypes, and set back HIV and other STI prevention efforts.
There is a high appetite for increased access to pre-exposure prophylaxis (PrEP) among gay app users in Switzerland, according to research looking into the need for a national PrEP programme.
Most healthcare providers cite worries over risk compensation after providing PrEP, but experiences among doctors who do prescribe PrEP are positive.
The game-changing drug, Truvada – the only drug approved for PrEP – will be offered to groups considered at risk of HIV.
The European Commission has given pharmaceutical company, Gilead, the green light to market Truvada as pre-exposure prophylaxis (PrEP) across the region.
National Health Service (NHS) England has decided against providing pre-exposure prophylaxis (PrEP) for HIV-negative people at a high risk of HIV, sparking outrage among a number of HIV charities and service providers in the UK.
The United States of America has in December, quietly and partially lifted their ban on federal funding for needle and syringe exchange programmes (NSPs).
Leading HIV and AIDS organisations have called for pre-exposure prophylaxis (PrEP) to be made available on the UK’s National Health Service (NHS).
Many people who use PEP for HIV are also highly likely to have a mental health issue, according to new research published in AIDS and Behaviour this month.